Utilisation and cost of health services in the last six months of life: a comparison of cohorts with and without cancer

Similar documents
Fall-related injury in people with dementia

Palliative Care and End of Life Care

WHAT FACTORS INFLUENCE AN ANALYSIS OF HOSPITALIZATIONS AMONG DYING CANCER PATIENTS? AGGRESSIVE END-OF-LIFE CANCER CARE. Deesha Patel May 11, 2011

The Cost of Waiting: Implications of the Timing of Palliative Care Consultation among a Cohort of Decedents at a Comprehensive Cancer Center

Introduction. Anthony W. Ireland 1,2. Abstract

Using linked data to tackle the big questions for health services policy and planning: When do linked datasets really add value?

Cancer in Australia: Actual incidence data from 1991 to 2009 and mortality data from 1991 to 2010 with projections to 2012

The Morbidity and Mortality of Kansas Drug Epidemic

Palliative Care & Private Health Insurance

A methodological protocol for selecting and quantifying low-value prescribing practices in routinely collected data: an Australian case study

Rates and patterns of participation in cardiac rehabilitation in Victoria

The Economic Burden of Hypercholesterolaemia

Inequalities in bariatric surgery in Australia: findings from 49,364. obese participants in a prospective cohort study

Balancing Glycemic Overtreatment and Undertreatment for Seniors: An Out of Range (OOR) Population Health Safety Measure

BMJ Open. Medical management. Keywords: Adult oncology < ONCOLOGY, Medical futility, Statins

Data Linkage. Dr Sradha Kotwal DNT Adelaide, Staff Specialist, Department of Nephrology Prince of Wales Hospital, Randwick, Sydney

The Illawarra Shoalhaven Local Health District. Setting a Research Agenda For or With Older People

Real-world observational data in costeffectiveness analyses: Herceptin as a case study

David Goldsbury, 1 Mark Fort Harris, 2 Shane Pascoe, 2 Ian Olver, 3 Michael Barton, 4 Allan Spigelman, 5 Dianne O Connell 1

PHARMO Database Network

Outcomes of rehabilitation for reconditioning: falls, frailty, care service requirements - what does the national data tell us?

Aboriginal and Torres Strait Islander Health Performance Framework Report

Cancer screening: Breast

Trends in fall-related ambulance use and hospitalisation among older adults in NSW from 2006 to 2013: a retrospective, population-based study

Palliative care services and home and community care services inquiry

Outcome Statement: National Stakeholders Meeting on Quality Use of Medicines to Optimise Ageing in Older Australians

Chronic conditions, physical function and health care use:

MidCentral District Health Board Rheumatic Fever Prevention Plan. October 2013

Initial analysis of newly added data items. Do they provide insights of value?

Issues using linkage of hospital records and death certificate data to determine the size of a potential palliative care population

Writing a PBS-RPBS prescription authorised optometrists

Exercise & Sports Science Australia Submission: global action plan to promote physical activity

Research SNAPSHOT. Palliative and End of Life Care Research Institute DECEMBER2017

CANCER IN NSW ABORIGINAL PEOPLES. Incidence, mortality and survival September 2012

Cost effectiveness analysis of advance care planning in Australia

AUSTRALIAN INFLUENZA SURVEILLANCE SUMMARY REPORT

Tennessee. Prescribing and Dispensing Profile. Research current through November 2015.

Eye injection treatment costs and rebates

Rural and remote health care research funding at NHMRC opportunities and barriers

Attendance rates and outcomes of cardiac rehabilitation in Victoria, 1998

Value of Hospice Benefit to Medicaid Programs

Who do Australian general practitioners refer to physiotherapy?

Oral health trends among adult public dental patients

The long run impact of child abuse on health care costs and wellbeing in Australia

THE EPIDEMIOLOGY OF RESPIRATORY SYNCYTIAL VIRUS INFECTIONS IN NSW CHILDREN,

Quality ID #457 (NQF 0216): Proportion Admitted to Hospice for less than 3 days- National Quality Strategy Domain: Effective Clinical Care

Jukti Kumar Kalita, PhD Business Analytics and Insights Pfizer Presented at:

Zhao Y Y et al. Ann Intern Med 2012;156:

NATIONAL ORAL HEALTH PLAN MONITORING GROUP. KEY PROCESS AND OUTCOME PERFORMANCE INDICATORS Second follow-up report

Care Received by Patients with Advanced Dementia in Their Final Days of Life - A Retrospective Study

Eye injection treatment costs and rebates

Inequalities in bariatric surgery in Australia: findings from obese participants in a prospective cohort study

Use of Anti-Psychotic Agents in Irish Long Term Care Residents with Dementia

At the heart of health promotion: Health Promotion Policy & Advocacy. Rachelle Foreman

Weight loss surgery in Australia Australian hospital statistics

Use, access to, and impact of Medicare services for Australian women: Findings from the Australian Longitudinal Study on Women s Health Julie Byles

Physician specialty and the outcomes and cost of admissions for end-stage liver disease Ko C W, Kelley K, Meyer K E

VISITING YOUR LOCAL GP PRACTICE: A GUIDE

Influenza disease burden in Australia

Research and Innovation in Aging Forum December 15, 2015

Spending estimates from Cancer Care Spending

NSW Medical Energy Rebate

Evidence-Based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine in People with Dementia

Breast Cancer Risk and Disease Outcomes for Australian Aboriginal Women

Changes to Australian Government Hearing Services Program and Voucher scheme

The Cancer Council NSW

The Cancer Council NSW. Submission to the Legislative Assembly Public Accounts Committee. Inquiry into NSW State Plan Reporting

- The University of. - Student. Western Australia, Crawley, Western Australia

The state of asthma in South Australia

The PERISCOPE Study. 13th Australian Palliative Care Conference 1-4 September, 2015 Melbourne, Australia

Do Elderly Men Have Increased Mortality Following Hip Fracture?

8/31/2010. ELNEC- For Veterans. Hospice Education Network - ELNEC - For Veterans Module 1 - Introduction to Palliative Care

Accidental drug-induced deaths due to opioids in Australia, 2013

Drug related hospital stays in Australia

Cancer in Australia: Actual incidence data from 1982 to 2013 and mortality data from 1982 to 2014 with projections to 2017

Etat des lieux des traitements méthadone et buprénorphine. A/Prof Adrian Dunlop Biarritz 2015

Clinical Trial of a Supportive Care Team for Patients With Advanced Cancer

When a Threshold Crossing approach may and may not be appropriate: A Case Study in SMA

Quality of End-of-Life Care in Patients with Hematologic Malignancies: A Retrospective Cohort Study

PHYSIOTHERAPY AND DIABETES

Cocaine and Methamphetamine related drug-induced deaths in Australia, 2011

A comparison of treatment options for management of End Stage Kidney Disease in elderly patients: A systematic review protocol

THE IMPORTANCE OF COMORBIDITY TO CANCER CARE AND STATISTICS AMERICAN CANCER SOCIETY PRESENTATION COPYRIGHT NOTICE

Opioid use in COPD: balancing benefits and harms. St. Michael s Hospital, University of Toronto

Primary Health Networks

Brian Draper 1, Diane Gibson 2 Ann Peut 3, Rosemary Karmel 3,Charles Hudson 3, Le Anh Pham Lobb 3, Gail Brien 3, Phil Anderson 3.

Exposure to potentially inappropriate medications among long-term care residents with cognitive impairment in Ontario:

Acceptance onto dialysis guidelines: St George Hospital

The Cost to Close the Gap for Vision

PRACTICAL TIPS FOR LOOKING AFTER YOUR SKIN

INTEGRATE Project. Integrating a palliative care approach earlier in the disease trajectory

Significant events in immunisation policy and practice* in Australia

BC Methadone Maintenance System

Proton pump inhibitors and the risk of pneumonia: a comparison of cohort and self-controlled case series designs

Submission on the Draft National Clinical Practice Guidelines for Dementia in Australia

Reaping the Benefits of Cancer Registries: Examples from End of Life Studies

Clinical and economic outcomes of an ambulatory urinary tract infection disease management program Armstrong E P

PATIENTS WHO WITHDRAW FROM DIALYSIS. Dr Katalin Urban Palliative Care Specialist Greenwich Hospital

Impact of pre-treatment symptoms on survival after palliative radiotherapy An improved model to predict prognosis?

Aboriginal Health Data for Our Region. Newcastle/Hunter Aboriginal Partnership Forum Planning Day July 2017

Transcription:

Utilisation and cost of health services in the last six months of life: a comparison of cohorts with and without cancer Rebecca Reeve, Preeyaporn Srasuebkul, Marion Haas, Sallie Pearson, Rosalie Viney on behalf of the EOL-CC team: J Langton 1, P Srasuebkul 1, R Reeve 2, B Parkinson 2, M Haas 2, R Viney 2, S Pearson 1 1: Faculty of Pharmacy, The University of Sydney; 2: CHERE, University of Technology Sydney

Background and motivation The last year of life is one of the most resource and cost intensive periods in cancer care Understanding patterns of care provides evidence to inform resource allocation and planning decisions There has been little research on end of life care in Australia (most existing research is in North America) Most existing Australian research focuses solely on hospital care or palliative care Few studies comparing cancer and non-cancer cohorts Observational studies using linked administrative datasets provide an approach to understanding patterns of care at the end of life 2

Existing literature* 78 studies of end-of-life cancer care 55 from North America 33 published since 2008 71 examined resource use alone (52) or in combination with costs (19) 30 focus on only one aspect of resource use 7 costs only 15 quality of care indicators none Australian and only 1 with non-cancer comparator 5 local studies Focused on use of palliative care services, hospital admissions and emergency department presentations All but one study conducted in the Western Australia Only one included data from the last decade Opportunities!!! * Langton J et al End-of-life resource utilization and costs: A systematic review of retrospective observational studies of cancer decedents using health administrative data (1990-2011) article forthcoming in Palliative Medicine 3

Langton J et al End-of-life resource utilization and costs: A systematic review of retrospective observational studies of cancer decedents using health administrative data (1990-2011) article forthcoming in Palliative Medicine 4

Aims and objectives To undertake a program of research using linked data to examine resource use, costs and quality of end of life care and to investigate the factors associated with these outcomes for cancer and non-cancer patients. In our first study within this program of research: To quantify resource use and costs in the last 6 months of life in a cohort of elderly decedents To compare resource use and costs for decedents with and without a cancer diagnosis To examine the distribution of resource use and costs across different types of medical services at the end of life To determine the predictors of resource use and costs at the end of life To examine trends in resource use and costs over the 6 months to death 5

Study population and data sources Department of Veterans Affairs (DVA) gold card holders who died between 2005 and 2009 and resided in NSW for the last 18 months of life - DVA clients include eligible veterans, war widows and widowers and their dependents - Gold card holders are funded by the DVA for treatment of all health conditions - PBS, RPBS, other sundry pharmaceutical items - MBS, dental and allied health services - Hospitalisations and emergency presentations 6

Study population and data sources Age >=65 at death, Last 6 months (180 days) of life Cancer cohort, N=9,862: identified by notifiable cancer diagnosis or cause of death (CCR and ABS) Non-cancer cohort, N=15,483: no notifiable cancer diagnosis (also excluded if received any cancer-related services) Datasets linked by the CHeReL (provided by the DVA and NSW ministry of health) DVA client database PBS and RPBS and additional DVA approved items MBS, dental and allied health NSW registry of births deaths and marriages NSW Central Cancer Registry Admitted patient data collection Emergency department data collection 7

Methods: utilisation Compare utilisation of services for cancer and non-cancer patients by service type and patient characteristics Report on utilisation of services in last 6 months of life and by proximity to death (months to death) Medicines (includes PBS, RPBS and sundry items) Health care services (MBS, dental, community nursing, allied health) Hospital admissions (episodes of care) Emergency department visits Negative binomial regression of predictors of resource utilisation * Detailed methods outlined in Langton et al Resource use, costs and quality of end of life care: Observations in a cohort of elderly Australian cancer decedents under review by the DVA, to be submitted as a protocol paper 8

Methods: costs Allocate costs to resource items and report by service type and overall for cancer and non-cancer patients. All costs expressed in common year (2009/10 reflecting most recently published NSW Cost of Care Standards Report) NSW Cost of Care Standards used to derive hospitalisations and ED costs in last 6 months of life.* Medications and health care services costs inflated to 2009/10 using inflation rates derived from AIHW published price indices. Report on utilisation of services in last 6 months of life and by proximity to death (months to death) Negative binomial regression of predictors of total resource cost * See Reeve and Haas, 2014, Estimating the cost of Emergency Department presentations in NSW. CHERE Working Paper 2014/01'. 9

Cohort characteristics 10 Cancer (n=9862) Non Cancer (n=15,483) Sex, F% : M% 31.6 : 68.4 48.9 : 51.4 Median age at death (range), years 86 (65-107) 87 (65-111) Age 85+ at death, % 55.7 65.9 SEIFA decile, % 1-2 Most disadvantaged 11.8 12.0 3-4 28.7 28.9 5-6 20.6 19.9 7-8 14.4 14.5 9-10 Least disadvantaged 20.5 20.6 Unknown 4.1 4.1 Remoteness area, % Major cities 62.3 61.6 Inner Regional 28.2 28.4 Outer Regional 8.8 9.1 Remote 0.4 0.5 Very Remote 0.1 0.0 Unknown 0.2 0.4 Co-morbidity burden % 0 4.9 5.5 1-2 13.4 13.8 3-5 39.9 39.5 > 6 41.8 41.2

Resource utilisation in the last 6 months of life Utilisation Emergency visits Hospital episodes Health care services, OOH Health care services, OOH + in hospital Non-Cancer Cancer Prescribed medicines 0 10 20 30 40 50 60 70 80 90 100 Mean resources utilised Health care services include MBS, dental, community nursing and allied health items 11

Resource costs in the last 6 months of life Cost Emergency visits Hospital episodes Health care services, OOH Health care services, OOH + in hospital Non-Cancer Cancer Prescribed medicines Mean resource cost Health care services include MBS, dental, community nursing and allied health items 12

Mean ED cost per person per month Mean ED visits per person per month 0.6 0.5 0.4 0.3 0.2 0.1 0 Resource utilisation and costs by month to death: ED visits Utilisation 6 5 4 3 2 1 Month to death Cancer Non-Cancer 300 250 200 150 100 50 0 Cost 6 5 4 3 2 1 Month to death Cancer Non-Cancer 13

Mean hospital episodes per person per month Mean hospital cost per person per month Resource utilisation and costs by month to death: Hospital episodes Utilisation 1.2 1 0.8 0.6 0.4 0.2 0 6 5 4 3 2 1 Month to death Cancer Non-Cancer 12000 10000 8000 6000 4000 2000 0 Cost 6 5 4 3 2 1 Month to death Cancer Non-Cancer 14

Mean health care services cost per person per month Mean health care services per person per month Resource utilisation and costs by month to death: Health care services* 30 25 20 15 10 5 0 Utilisation 6 5 4 3 2 1 Month to death Cancer Non-Cancer 2,500 2,000 1,500 1,000 500 0 Cost 6 5 4 3 2 1 Month to death Cancer Non-Cancer * Includes MBS, dental, community nursing and allied health items (in and out of hospital) 15

Mean prescribed medicine cost per person per month Mean prescribed medicines per person per month Resource utilisation and costs by month to death: prescribed medicines 10 8 6 Utilisation 4 2 Cancer Non-Cancer 0 6 5 4 3 2 1 Month to death Cost 400 300 200 100 0 6 5 4 3 2 1 Month to death Cancer Non-Cancer 16

Total resource costs by month to death: Cancer cohort 17

Total resource costs by month to death: Non-Cancer cohort 18

Regression results: ED presentations Results expressed as incident rate ratios (IRR) base category IRR = 1 Also controlled for sex, year of death, comorbidities (Charlson and Rx risk) 19

Regression results: Hospital episodes Results expressed as incident rate ratios (IRR) base category IRR = 1 Also controlled for sex, year of death, comorbidities (Charlson and Rx risk) 20

Regression results: Health care services Results expressed as incident rate ratios (IRR) base category IRR = 1 Also controlled for sex, year of death, comorbidities (Charlson and Rx risk) 21

Regression results: Prescription medicines Results expressed as incident rate ratios (IRR) base category IRR = 1 Also controlled for sex, year of death, comorbidities (Charlson and Rx risk) 22

Regression results: Total cost of EoL care Results expressed as incident rate ratios (IRR) base category IRR = 1 Also controlled for sex, year of death, comorbidities (Charlson and Rx risk) 23

Discussion Previous local research has focused on hospitalisations, ED and palliative care (in NSW only hospitalisations) We have extended this to provide a more complete picture over multiple resource types People with cancer have higher total EoL health care costs and use more of all resource types Our findings with respect to decreased EoL costs for hospitalisations in older age groups is consistent with NSW general population research Our findings also suggest that overall recourse use and costs of care to the health system are lower for older age cohorts This has implications for planning in the context of an ageing population whilst more people are aged >65 more will be dying at older ages 24

Future analyses Detailed investigation of utilisation and costs by subcategories of resource types Subgroup analyses by patient characteristics Disaggregate cancer cohort by whether cancer was the cause of death (58.9% of cancer cohort died of cancer) Investigate specific cancer types Develop indicators of quality of care for our data based on international validated indicators identified in the literature and report on these (examples to follow) Expand our approach to a general population Inform data collections by CINSW and CCNSW collecting and making better use of data 25

Aggressiveness of Care Indicators Rate (%)* Previous Studies Chemotherapy Last 14 days 1-19 7 Last 30 days 10-38 3 Emergency Department Visits Last 14 days 27-37 3 >1 visit last 30 days 7-19 6 Hospital Admissions Last 7 days 16 1 Last 30 days 45-64 2 >1 admission last 30 days 8-33 4 >14 days of last 30 days in hospital 11-58 3 Intensive Care Unit Admissions Last 14 days 5-6 2 Last 30 days 3-19 6 Life Sustaining Treatments CPR last 30 days 7-12 2 Intubation last 30 days 17-27 2 Mechanical ventilation last 30 days 19-33 2 * Rate = average rate of use in cancer cohort (if reported) in previous studies Langton J et al End-of-life resource utilization and costs: A systematic review of retrospective observational studies of cancer decedents using health administrative data (1990-2011) article forthcoming in Palliative Medicine 26

Palliative Care Indicators Rate (%)* Previous Studies Hospice Enrolment 3 days before death (late enrolment) 11-36 6 7 days before death (late enrolment) 19-23 2 No enrolment last 30 days 66 1 Enrolment duration 2 months (appropriate enrolment) 6-29 2 Prior to death 51-57 2 >180 days before death (inappropriate enrolment) 6-8 1 Opioids Outpatient prescription short- or long-acting last 30 days 25 1 Outpatient prescription short- or long-acting last 60 days 46 1 Other Physician house call last 14 days 25-28 1 Community follow-up last 6 months 16 1 Home care last 6 months 21-78 2 * Rate = average rate of use in cancer cohort (if reported) in previous studies Langton J et al End-of-life resource utilization and costs: A systematic review of retrospective observational studies of cancer decedents using health administrative data (1990-2011) article forthcoming in Palliative Medicine 27

Acknowledgements This research is supported by a NHMRC Capacity Building Grant (571926) and a Cancer Australia Grant (568773). S Pearson is also supported by a Cancer Institute NSW Career Development Fellowship (09/CDF/2-37) Special thanks to the Department of Veterans Affairs and their clients 28